Q2 2021
Released Aug 5, 2021, after the close
10-Q filed Aug 5, 2021, 36 days after period end · 0001493152-21-018725
Q2 2021 · 10-Q
Revenue$2.27M$2.27M +43.7% vs Q2 2020−17.2% vs Q1 2021
Net Income-$1.13M-$1.13M N/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$0.12-$0.12 N/M vs Q2 2020N/M vs Q1 2021
Gross Profit$1,275,000+42.5%
Operating Income-$1,117,000N/M
Operating Cash Flowderived-$117,000N/M
Free Cash Flowderived-$117,000—
Margins · derived
Gross margin56.3%−0.5 pt vs Q2 2020
Operating margin-49.3%+52.0 pt vs Q2 2020
Net margin-49.7%+55.4 pt vs Q2 2020
What the release said
The release
Same quarter
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | $2.27M | $1.58M | $2.31M | $1.37M |
| Net Income | -$1.13M | -$1.66M | -$942.00K | -$682.00K |
| EPS Diluted | -$0.12 | -$0.19 | -$0.14 | -$0.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nephros Inc · CIK 1196298 · Engraved from SEC EDGAR